/
AURX
$1.01+$0.00 (+0.00%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.84 – $3.23
7% from low
Exchange
OTC Link
CS
Borrow rate
5.52%
Hard to borrow
Price (6 mo)
Loading chart…
Change+$1.01
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $146.2K | $0 | $0 | $112.3K | $608.5K | $1.4M | $3.3M |
| Cost of revenue | $163.0K | $114.6K | $0 | $0 | $19.2K | $126.1K | $302.8K | $1.1M |
| Gross profit | $1.2M | $31.6K | $0 | $0 | $93.0K | $482.4K | $1.1M | $2.2M |
| Gross margin | 88.1% | 21.6% | — | — | 82.9% | 79.3% | 77.8% | 66.9% |
| R&D | $576.2K | $181.2K | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$1.5M | −$969.2K | −$378.1K | −$90.7K | −$3.3M | −$3.2M | −$2.5M | −$2.5M |
| EBITDA | −$1.4M | −$879.3K | −$288.2K | −$90.7K | −$3.1M | −$3.1M | −$2.4M | −$2.4M |
| Net income | −$1.5M | −$1.4M | −$139.3K | −$90.7K | −$3.0M | −$3.2M | −$2.3M | −$2.5M |
| Net margin | -112.5% | -968.9% | — | — | -2695.1% | -521.2% | -170.2% | -75.8% |
| EPS (diluted) | -0.07 | -0.06 | -0.01 | -0.00 | -0.08 | -0.08 | -0.05 | -0.05 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $6M | $-0.04 | $-0.04–$-0.04 | 1 |
| 2027 | $10M | $-0.01 | $-0.01–$-0.01 | 1 |
| 2028 | $14M | $0.01 | $0.01–$0.01 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
NUO THERAPEUTICS INC NEW
NUO THERAPEUTICS INC NEW
Held by traders on TradeandTell
No one on the platform currently holds AURX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in AURX as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded AURX yet.